A retrospective real-world study: the efficacy of immune-related combination therapies in advanced non-small cell lung cancer after resistance to EGFR-TKIs

Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

(2022) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial

(2022) Shun Lu et al.   LANCET ONCOLOGY

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

(2022) Solange Peters et al.   NATURE MEDICINE

Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy

(2022) Shujie Zhou et al.   Frontiers in Immunology

The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study

(2022) Jia Hu et al.   Frontiers in Immunology

The impact of osimertinib’ line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance

(2021) Vered Fuchs et al.   LUNG CANCER

Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges

(2021) Shujie Zhou et al.   CANCER LETTERS

Immune checkpoint inhibitors in EGFR-mutated non-small cell lung cancer: Dusk or Dawn?

(2021) Meng Qiao et al.   Journal of Thoracic Oncology

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

(2021) Mark A. Socinski et al.   Journal of Thoracic Oncology

Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non–Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407

(2021) Steven F. Powell et al.   Journal of Thoracic Oncology

Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC

(2021) Michael J. Grant et al.   Nature Reviews Clinical Oncology

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

(2021) Naoyuki Nogami et al.   Journal of Thoracic Oncology

Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial

(2021) Shun Lu et al.   Journal of Thoracic Oncology

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

(2020) Shirish Gadgeel et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11)

(2020) Yunpeng Yang et al.   Journal of Thoracic Oncology

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

(2019) Tony S K Mok et al.   LANCET

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

(2019) Howard West et al.   LANCET ONCOLOGY

Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib

(2019) Yuxin Mu et al.   Targeted Oncology

Exon-16-skipping HER2 as a novel mechanism of osimertinib-resistance in EGFR L858R/T790M-positive non-small-cell lung cancer

(2019) Chia-Chi Hsu et al.   Journal of Thoracic Oncology

Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastases

(2019) Zhen Wang et al.   International Journal of Clinical Oncology

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients

(2018) J Remon et al.   ANNALS OF ONCOLOGY

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

(2018) D Westover et al.   ANNALS OF ONCOLOGY

A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC

(2018) A. Lisberg et al.   Journal of Thoracic Oncology

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality

(2017) Andreas Pircher et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

(2017) Leora Horn et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

(2017) Elizabeth Allen et al.   Science Translational Medicine

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

(2016) Corey J Langer et al.   LANCET ONCOLOGY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?

(2015) L. Apetoh et al.   ANNALS OF ONCOLOGY

Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study

(2015) B. Besse et al.   CLINICAL CANCER RESEARCH

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy inEGFR-Mutant Lung Cancer: A Meta-Analysis

(2015) Chee Khoon Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer

(2015) Caicun Zhou et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

(2015) Naiyer A Rizvi et al.   LANCET ONCOLOGY

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

(2012) Julian R. Molina et al.   MAYO CLINIC PROCEEDINGS

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

(2010) M. Reck et al.   ANNALS OF ONCOLOGY